Defibrinogenating effect of batroxobin (Defibrase®) in rats and inhibition of migration of human vascular smooth muscle cells by the plasma of batroxobin-treated rats in vitro

Atherosclerosis

Volumn 156, Issue 1, 2001, Pages 73-80

  Wang, Dian Sheng ^a   Hanamoto, Mitsue ^a   Fang, Fang ^a   Ohba, Mitsuoki ^a   Ishii, Makoto ^a   Kimura, Fumio ^a   Higaki, Etsuji ^a   Senga, Hirobumi ^a  

^a Tobishi Pharmaceutical Co Ltd   (Japan)

Author keywords

Batroxobin (Defibrase ); Cell migration; ELISA; Fibrinogen; Human vascular smooth muscle cell; Rat plasma; Rat serum

Indexed keywords

BATROXOBIN; FIBRINOGEN;

ANIMAL EXPERIMENT; ARTICLE; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FIBRINOGEN BLOOD LEVEL; FIBROGENESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PLASMA; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; BATROXOBIN; BLOOD PHYSIOLOGY; CELL MOVEMENT; CELLS, CULTURED; FIBRINOGEN; FIBRINOLYTIC AGENTS; HUMANS; MALE; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, WISTAR;

EID: 0035023517     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(00)00628-6     Document Type: Article

References (30)

1. Blombäck B., Hessel B., Hogg D., Therkildsen L. A two-step fibrinogen-fibrin transition in blood coagulation. Nature. 275:1978;501-505.
2. Vindigni A., Di Cera E. Release of fibrinopeptides by the slow and fast forms of thrombin. Biochemistry. 35:1996;4417-4426.
3. Aronson D.L. Comparison of the actions of thrombin and the thrombin-like venom enzymes ancrod and batroxobin. Thromb. Haemost. 36:1976;9-13.
4. Kwaan H.C., Barlow G.H. The mechanism of action of a coagulant fraction of Malayan pit viper venom, avrin, and of reptilase. Thromb. Diath. Haemorrh. 45:(Suppl.):1971;63-68.
5. Ohba M., Aoyama M. Defibrinogenating effects of batroxobin (DF-521) on plasma fibrinogen concentration of experimental animals: a comparative study on seven different species. Med. Sci. Pharmacol. 14:1985;1061-1071. (article in Japanese, abstract in English).
6. Furukawa K. Reconstructive arterial surgery in peripheral obliterative atherosclerosis. Jpn. J. Surg. 80:1979;1135-1138. (article in Japanese, abstract in English).
7. Agishi Y., Uchiumi T., Shirakawa H., Oku T., Kishi H., Saito K., Yoshimatsu S., Kato M., Fukushima T., Habu K., Nasu Y., Fujimaki M., Furukawa K., Mishima Y. Clinical investigation of defibrinogenating therapy on peripheral circulation disturbance of vibration syndrome patients. Clin. Med. 1:1985;1145-1168. (article in Japanese, abstract in English).
8. Shiraishi T., Kubo T., Okumura S., Naramura H., Nishimura M., Okusa M., Matsunaga T. Hearing recovery in sudden deafness patients using a modified defibrinogenation therapy. Acta Otolaryngol. (Stockh). 501:(Suppl.):1993;46-50.
9. Tomaru T., Uchida Y., Nakamura F., Sonoki H., Tsukamoto M., Sugimoto T. Enhancement of arterial thrombolysis with native tissue-type plasminogen activator by pretreatment with heparin or batroxobin: an angioscopic study. Am. Heart J. 117:1989;275-281.
10. Namikata S., Sato S., Yoshida M., Nishikawa T., Takenaga K., Senga Y. Effects of snake venom batroxobin (Defibrase) on cerebral infarction in a rat model. Jpn. Pharmacol. Ther. 20:1992;2393-2405. (article in Japanese, abstract in English).
11. Schafer A.I. The hypercoagulable states. Ann. Intern. Med. 102:1985;814-828.
12. Ernst E. Fibrinogen: its emerging role as a cardiovascular risk factor. Angiology. 45:1994;87-93.
13. Heinrich J., Assmann G. Fibrinogen and cardiovascular risk. J. Cardiovasc. Risk. 2:1995;197-205.
14. Sweetnam P.M., Thomas H.F., Yarnell J.W.G., Beswick A.D., Baker I.A., Elwood P.C. Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease: The Caerphilly and Speedwell Studies. Eur. Heart J. 17:1996;1814-1820.
15. Ishida T., Tanaka K. Effects of fibrin and fibrinogen-degradation products on the growth of rabbit aortic smooth muscle cells in culture. Atherosclerosis. 44:1982;161-174.
16. Smith E.B. Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis. Clin. Haematol. 15:1986;355-370.
17. Naito M., Hayashi T., Kuzuya M., Funaki C., Asai K., Kuzuya F. Effects of fibrinogen and fibrin on the migration of vascular smooth muscle cells in vitro. Atherosclerosis. 83:1990;9-14.
18. Liu J.B., Wang L.H., Gao M., Tang C.S. Effect of batroxobin on vascular smooth muscle cell proliferation induced by balloon angioplasty in rat aorta. Chin. J. Intervent. Cardiol. 4:1996;180-182. (article in Chinese, abstract in English).
19. Hidaka Y., Eda T., Yonemoto M., Kamei T. Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733). Atherosclerosis. 95:1992;87-94.
20. Doolittle F.R. Fibrinogen. Seligson D., Schmidt R.M. Handbook Series in Clinical Laboratory Science, Section I. 3:1980;3 CRC Press, Boca Raton, FL.
21. Bini A., Fenoglio J.J. Jr, Mesa-Tejada R., Kudryk B., Kaplan K.L. Identification and distribution of fibrinogen, fibrin, and fibrinon(ogen) degradation products in atherosclerosis: use of monoclonal antibodies. Arteriosclerosis. 9:1989;109-121.
22. Naito M., Nomura H., Iguchi A., Thompson W.D., Smith E.B. Effect of crosslinking by factor XIIIa on the migration of vascular smooth muscle cells into fibrin gels. Thromb. Res. 90:1998;111-116.
23. Sugai K., Imamura Y., Mihashi S., Ohba M., Kunikane K., Mori N., Baba S. Plasma levels and urinary excretion of batroxobin and its defibrinogenating effects in various animal species. J. Toxicol. Sci. 11:1986;135-143.
24. Koyama N., Morisaki N., Saito Y., Yoshida S. Regulatory effects of platelet-derived growth factor-AA homodimer on migration of vascular smooth muscle cells. J. Biol. Chem. 267:1992;22806-22812.
25. Koyama N., Koshikawa T., Morisaki N., Saito Y., Yoshida S. Secretion of a potent new migration factor for smooth muscle cells (SMC) by cultured SMC. Atherosclerosis. 86:1991;219-226.
26. Schrör K., Weber A.A. Roles of vasodilatory prostaglandins in mitogenesis of vascular smooth muscle cells. Agents Actions. 48:(Suppl.):1997;63-91.
27. Wang W., Chen H.J., Schwartz A., Cannon P.J., Rabbani L.E. T cell lymphokines modulate bFGF-induced smooth muscle cell fibrinolysis and migration. Am. J. Physiol. 272:1997;C392-C398.
28. Bonner J.C., Osornio-Vargas A.R. Differential binding and regulation of platelet-derived growth factor A and B chain isoforms by alpha 2-macroglobulin. J. Biol. Chem. 270:1995;16236-16242.
29. Engel L., Ryan U. TGF-beta 1 reverses PDGF-stimulated migration of human aortic smooth muscle cells in vitro. In Vitro Cell. Dev. Biol. Anim. 33:1997;443-451.
30. Tomaru T., Yoshimura A., Aoki N., Omata M., Geschwind H.J., Uchida Y. Local delivery of antithrombotic drug inhibits neointimal hyperplasia following arterial injury. J. Intervent. Cardiol. 10:1997;51-60.